Stockreport

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

AEON Biopharma, Inc. Class A  (AEON) 
PDF FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway  Company continues to execute its analytical program [Read more]